Grant of Options

Source: RNS
RNS Number : 4662U
Cambridge Cognition Holdings PLC
01 July 2024
 

Cambridge Cog_U.K Header AW.jpg

1 July 2024

 

Cambridge Cognition Holdings plc

("Cambridge Cognition" or the "Company")

 

Grant of Options

 

Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, announces that on 28 June 2024, the Company granted options (the "Options") over a total of 903,574 ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares") pursuant to the Company's 2022 Long Term Incentive Plan ("LTIP").

 

The Options include:

 

1. Options over 354,421 Ordinary Shares granted to Persons Discharging Managerial Responsibilities ("PDMRs") as follows:

 

Name

Role

Number of Ordinary Shares over which Options Granted

Total number of Ordinary Shares over which Options held following Grant

Total number of Ordinary Shares held

Percentage of Current Issued Share Capital Held

Matthew Stork

Chief Executive Officer

192,307

1,332,504

223,950

0.54%

Alex Livingstone- Learmonth

Chief Commercial Officer

115,384   

115,384

10,000

0.02%

Ricky Dolphin

Chief Technology Officer

46,730

311,589

120,584

0.29%

 

2. Options over 549,153 Ordinary Shares granted to other employees of the Company.

The Options granted to the PDMRs are in each case "performance share awards" that are exercisable at a price of 1 pence per Ordinary Share from three years following the date of award until the tenth anniversary of the date of award, subject to continued service and to the extent to which challenging performance conditions are achieved.

 

Under the terms of the aforementioned performance conditions, one-half of each of the Options is subject to sliding scale compound annual growth rate targets for adjusted revenue over the three year period ending 31 December 2026, the other half of each of the Options is subject to a sliding scale measure of relative total shareholder performance over a three year period that commenced on the grant of the Options.

 

The Options granted to other employees of the Company (save for one more performance share award) are exercisable at a price of 1 pence per Ordinary Share from three years following the date of award until the tenth anniversary of the date of award, and will vest subject to continued service (so called 'restricted share awards').

 

The LTIP has scope to grant both EMI awards and non-EMI awards and was recently adopted by the Board. The terms of the LTIP align to best practice expectations, including leaver terms and malus and clawback provisions.

 

Following the grant of Options, the total number of options outstanding over unissued Ordinary Shares is 3,383,747 representing approximately 8.22% of the Company's issued share capital.

 

Enquiries

 

Cambridge Cognition Holdings plc


Matthew Stork, Chief Executive Officer

Stephen Symonds, Chief Financial Officer

Tel: 01223 810 700

press@camcog.com



Panmure Liberum Limited (NOMAD and Joint Broker)

Tel: 020 78862500

Freddy Crossley / Emma Earl / Mark Rogers

(Corporate Advisory)

Rupert Dearden

(Corporate Broking)



Dowgate Capital Limited (Joint Broker)

David Poutney/ James Serjeant

Tel: 020 3903 7715

(Corporate Broking)



Hudson Sandler (Financial PR and IR)

Tel: 020 7796 4133

Dan de Belder/Hattie Dreyfus


 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM:

 

1. 

Details of the person discharging managerial responsibilities / person closely associated

a)

Names

Matthew Stork - Chief Executive Officer

Alex Livingstone - Learmonth - Chief Commercial Officer

Ricky Dolphin - Chief Technology Officer

2. 

Reason for the Notification

a)

Position/status

See 1(a) above for positions - all classified as PDMRs of the Company

b)

Initial notification/ Amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Cambridge Cognition Holdings plc

b)

LEI

213800SZKDIN122EPA96

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

In each case, the grant of Options over Ordinary Shares on 28 June 2024

 

Identification code

GB00B8DV9647

b)

Nature of the transaction

Grant of Options over Ordinary Shares each with an exercise price of 1 pence per Ordinary Share

 

c)

Price(s) and volume(s)

Price: n/a

Volumes:

Matthew Stork - Options over 192,307 Ordinary Shares

Alex Livingstone-Learmonth - Options over 115,384 Ordinary Shares

Ricky Dolphin -   Options over 46,730 Ordinary Shares

d)

Aggregated information:

·       Aggregated volume

·       Price

 

354,421
n/a

e)

Date of the transaction

28 June 2024

f)

Place of the transaction

Outside a trading venue

 

About Cambridge Cognition

 

Cambridge Cognition is a technology company marketing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

 

For further information visit www.cambridgecognition.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHKVLFLZQLBBBD